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Trivalent Combination Vaccine Induces Broad
Heterologous Immune Responses to Norovirus and
Rotavirus in Mice
Kirsi Tamminen, Suvi Lappalainen, Leena Huhti, Timo Vesikari, Vesna Blazevic*
Vaccine Research Center, University of Tampere School of Medicine, Tampere, Finland
Abstract
Rotavirus (RV) and norovirus (NoV) are the two major causes of viral gastroenteritis (GE) in children worldwide. We
have developed an injectable vaccine design to prevent infection or GE induced with these enteric viruses. The
trivalent combination vaccine consists of NoV capsid (VP1) derived virus-like particles (VLPs) of GI-3 and GII-4
representing the two major NoV genogroups and tubular RV recombinant VP6 (rVP6), the most conserved and
abundant RV protein. Each component was produced in insect cells by a recombinant baculovirus expression system
and combined in vitro. The vaccine components were administered intramuscularly to BALB/c mice either separately
or in the trivalent combination. High levels of NoV and RV type specific serum IgGs with high avidity (>50%) as well
as intestinal IgGs were detected in the immunized mice. Cross-reactive IgG antibodies were also elicited against
heterologous NoV VLPs not used for immunization (GII-4 NO, GII-12 and GI-1 VLPs) and to different RVs from cell
cultures. NoV-specific serum antibodies blocked binding of homologous and heterologous VLPs to the putative
receptors, histo-blood group antigens, suggesting broad NoV neutralizing activity of the sera. Mucosal antibodies of
mice immunized with the trivalent combination vaccine inhibited RV infection in vitro. In addition, cross-reactive T cell
immune responses to NoV and RV-specific antigens were detected. All the responses were sustained for up to six
months. No mutual inhibition of the components in the trivalent vaccine combination was observed. In conclusion, the
NoV GI and GII VLPs combination induced broader cross-reactive and potentially neutralizing immune responses
than either of the VLPs alone. Therefore, trivalent vaccine might induce protective immune responses to the vast
majority of circulating NoV and RV genotypes.
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Introduction
Acute gastroenteritis (AGE) is a leading cause of morbidity
and mortality in children all over the world [1]. Viruses are
responsible for a significant number of AGE cases and two
leading agents for viral gastroenteritis are rotavirus (RV) and
norovirus (NoV) [1]. Following the introduction of live RV
vaccines Rotarix® (GlaxoSmithKline plc, UK) and RotaTeq®
(Merck & Co., Inc., USA) into national immunization programs,
NoV’s epidemiological importance is rising and in some
countries NoV has already overtaken RV as the most important
cause of pediatric AGE [2–5].
Development of a NoV vaccine is underway [6–8]. Since the
cultivation of NoVs has not been successful [9], the main
direction in vaccine development has been the use of non-live
NoV virus-like particles (VLPs), which mimic the structure and
the antigenic properties of the native NoVs [10]. These VLPs
are constructed of the core protein VP1, which self-assembles
into VLPs when produced in vitro [10]. An additional challenge
in the NoV vaccine development is the high genetic variation of
NoVs [11]. The major NoV genogroups infecting human beings
are genogroup I (GI) and genogroup II (GII) with at least 25
different genotypes belonging in these genogroups [11]. There
is a great molecular variation inside the genotypes themselves
and the driving force in the evolution seems to be herd
immunity [12]. For over two decades the most prevalent NoV
genotype has been GII-4, currently accounting for over 80% of
all NoV cases [13,14]. There is some immunological cross-
reactivity between GI and GII genogroups [15] but no protective
immune responses across genogroups in humans have been
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observed [16]. It has been suggested that a broadly effective
NoV vaccine should be a combination of at least two
genotypes; one from each of the major genogroups [17–19].
RV annually accounts for ~450 000 deaths in children under
5 years of age, the majority of the deaths taking place in
developing countries [20]. Since the introduction of the two live-
attenuated RV vaccines, the cases of RV-caused AGE have
decreased dramatically [5,21,22]. Despite the efficacy of RV
vaccines, there are still certain limitations associated with both
of these vaccines. The introduction of the vaccines into
developing countries has been challenging [23] and safety
issues like increased risk of intussusception [24,25] and the
reassortment of vaccine viruses in higher virulence [26,27] are
concerns involved in the currently available live-attenuated RV
vaccines.
RV has a double stranded RNA genome enclosed in the
triple layered capsid [28]. VP7 forms a virion surface from
which spike-like structures (VP4) extend outwards and are
responsible for cell attachment [28]. The inner capsid consists
of VP6, which is highly antigenic and the most conserved RV
protein [28]. Although neutralizing antibodies targeted against
VP4 and VP7 are most strongly associated with RV immunity
[29], anti-VP6 antibodies and CD4+ T cells have also been
suggested to play a role in the protection [30–33]. RV
recombinant VP6 (rVP6) has the ability to form various
assemblies in vitro [34] and these structures are considered the
second-generation vaccine candidates for non-live RV vaccine
development [35].
We have previously shown that a dual combination of NoV
GII-4 VLPs and RV rVP6 tubules induced strong humoral
immune responses without mutual inhibition when delivered
parenterally into BALB/c mice [7]. In the present study we have
included GI-3 VLPs as a representative of GI NoVs into the
above combination in an attempt to broaden NoV-specific
immune responses. Induction and long-term duration of NoV
and RV-specific cell mediated immunity in addition to humoral
immune responses was investigated. Our data indicates that
the trivalent combination vaccine containing GII-4 VLPs, GI-3
VLPs, and rVP6 induces robust, long-lasting and broadly cross-
reactive NoV and RV-specific cellular immune responses and
antibodies with neutralizing abilities against both viruses.
Materials and Methods
Ethics Statement
The protocol for the study was approved by the Finnish
National Animal Experiment Board (permission number
ESLH-2009-06698/Ym-23). All the procedures performed on
the animals were conducted according to the guidelines of the
Finnish National Animal Experiment Board and all efforts were
made to minimize animal suffering.
Production and purification of NoV VLPs and rVP6
NoV GII-4 VLPs, GI-3 VLPs, GII-4 New Orleans (NO) VLPs,
GII-12 VLPs, GI-1 VLPs, and RV rVP6 used for immunizations
and/or as antigens in immunological assays were produced by
a baculovirus-insect cell expression system and purified by
sucrose gradients as previously described [7,36]. The
reference strains for each genotype were determined according
to the EMBL/Genbank classification and FBVE as the following:
AF080551 (GII-4-1999), AF414403 (GI-3-2001), GU445325
(GII-4 New Orleans, GII-4 NO-2010), AJ277618 (GII-12-1998),
AY502016.1 (GI-1-2001) and GQ477131 (RV G1P1A [8]-2007
derived VP6). The morphology, integrity, purity, in vitro
antigenicity and protein concentration were determined for
each protein as described previously [7,36].
Cultivation of RVs in cell culture
The RV cultures used as antigens in the enzyme-linked
immunosorbent assay (ELISA) and enzyme-linked
immunosorbent spot (ELISPOT)-interferon-γ (IFN-γ) assays
were propagated in an MA104 cell line (ATCC CRL-2378, LGC
Standards, UK) as described by others [37]. In short, MA104
cells were infected with the human RV strains Wa (G1P1A [8]),
SC2 (G2P2 [6]), BrB (G4P2 [6]), 69M (G8P4 [10]), L26
(G12P1B [4]), bovine WC3 (G6P7 [5]), and rhesus rotavirus
(RRV, G3P5B [3]) and after observing the maximum cytopathic
effect (3-4 days respectively), the viruses were collected and
the VP6 protein amount in each culture was determined by
capture ELISA using insect cell-derived rVP6 as an internal
standard. The RV cell culture antigens were diluted in
phosphate-buffered saline (PBS) to contain equal quantities of
VP6 protein per each culture.
Mice immunizations and sample collections
To determine the optimal amount of each antigen, three
doses (3, 10 or 30 µg) of NoV GII-4 VLPs, GI-3 VLPs or RV
rVP6 were administered intramuscularly (IM) to 7-week-old
female BALB/c mice (Harlan laboratories, Horst, the
Netherlands). The mice were immunized (5 mice/group) at
study weeks 0 and 3 and euthanized at study week 5. After the
optimal dose selection, naïve BALB/c mice (5 mice/group) were
immunized in another set of experiments according to the
above schedule with a single NoV GII-4 VLPs, GI-3 VLPs or
RV rVP6 antigen (each at a 10 µg dose) or the trivalent
combination (10 µg GII-4 VLPs + 10 µg GI-3 VLPs + 10 µg
rVP6) and euthanized at study week 5. A group of mice
receiving the trivalent combination vaccine (7 mice/group) were
euthanized at study week 27 for the long-term follow-up of the
immune responses. Negative control groups of mice (5-7 mice/
group) received carrier only (PBS) and were terminated at
week 5 or week 27. Blood samples were collected at study
weeks 0 (pre-immune serum), 3, 4, 7, 12, 16, and 20 as
previously described [38]. Whole blood, feces, lymphoid tissues
and vaginal washes (VW) were collected at the time of
euthanization. Serum was separated from the blood of each
mouse and 10% (w/v) stool suspensions were prepared from
group-wise pooled stools according to the published
procedures [7]. Preparation of the cell suspensions and
freezing of the splenocytes were conducted as described
earlier [38]. VWs were collected by pipetting 2 × 125 µl of cold
PBS into the vagina 4-5 times up-and-down, after which the
VW were centrifuged at 12,000 × g for 10 minutes at +4°C and
the supernatant stored at -20°C.
Trivalent Combination Vaccine against NoV and RV
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NoV and RV-specific immunoglobulin (Ig) detection
from serum and IgG avidity assay
ELISA used to measure antigen-specific IgG, IgG1, and
IgG2a from serum is described in details elsewhere [7,38].
Briefly, 96-well half-area polystyrene plates (Corning Inc.,
Corning, NY) were coated with GII-4, GI-3, GII-4 NO, GII-12 or
GI-1 VLPs (0.4-1.5 µg/ml) or rVP6 (0.8 µg/ml). For the
detection of antibodies against various RV culture antigens
(described above) the plates were precoated with rabbit anti-
rotavirus polyclonal antibody (DakoCytomation, Glostrup,
Denmark) at 1 µg/ml in PBS followed by the addition of RV cell
culture antigens at VP6 antigen concentration of 0.1 µg/ml. The
serum samples (at 1:200 dilution or 2-fold dilution series) from
immunized and control mice were added to the plates and the
bound antibody was detected with HRP conjugated goat anti-
mouse IgG (Sigma-Aldrich, Saint Louis, MO), IgG1 (Invitrogen,
Carsbad, CA) or IgG2a (Invitrogen) followed by the reaction
with the OPD substrate (Sigma-Aldrich). The optical density
(OD) was measured at 490 nm (Victor2 1420; PerkinElmer,
Waltham, MA). The background signal from the blank wells
(wells without serum) was subtracted from all of the OD
readings at a plate. The cutoff value was calculated from the
wells of negative control mice serum as mean OD + 3 × SD. A
sample was considered positive if the net OD value was above
the set cut-off and at least 0.100 OD. End-point antibody titers
were defined as the highest dilution of serum giving an OD
above the set cut-off value. A Th2/Th1 response ratio was
calculated by dividing the end-point titer of IgG1 response with
the corresponding IgG2a titer.
Serum IgG avidity was measured by ELISA as described
above with an extra urea incubation step to remove the low
avidity antibodies [39,40]. The avidity index was calculated as
(OD with urea/OD without urea) × 100% and avidity index ≥
50% was considered high avidity.
NoV and RV-specific immunoglobulin (Ig) detection
from mucosal samples and RV-specific IgA detection
from serum
NoV-specific IgG content was tested from stool suspensions
(10% suspension) with the ELISA as described above. RV
rVP6-specific IgG and IgA in the stool suspensions and VWs
and rVP6-specific IgA in serum were detected by sandwich
ELISA as follows. The 96-well plate was first coated with rabbit
anti-rotavirus polyclonal antibody (DakoCytomation, Glostrup,
Denmark) at 1 µg/ml in PBS followed by the addition of rVP6 (1
µg/ml in PBS). After washing the unbound rVP6, 10% fecal
suspensions (serially diluted from 1:5), VW samples (diluted
1:5 for IgG detection and 1:2 for IgA detection) or serum
(diluted 1:2) were added and the plate was developed with
1:4000 diluted HRP conjugated goat anti-mouse IgG or IgA
(both from Sigma-Aldrich) and OPD substrate.
NoV VLP blocking assays
Saliva-based blocking assays were used as a surrogate
neutralization assay for NoV [41] and the procedure is
described in details elsewhere [38]. In brief, serum dilutions
from immunized and control mice were pre-incubated with NoV
VLPs (at concentrations 0.1-0.2 µg/ml) for 1 h at 37°C and
added to secretor positive human saliva type A (for GII-4, GII-4
NO and GI-3 VLPs binding) or type O (for GI-1 VLP binding)
coated 96-wells plates. VLPs lacking the serum were used for
maximum binding of VLPs to the saliva. The VLPs bound to
histo-blood group antigens (HBGAs) present in saliva were
detected with NoV antibody positive human serum [40] and
anti-human IgG-HRP (Invitrogen) following the OPD substrate
development. The blocking index (%) was calculated as 100%
– (OD wells with serum/OD wells without serum, maximum
binding) × 100%.
Inhibition of RV infectivity in vitro
The ability of mucosal and serum antibodies to abolish RV
infectivity in vitro was determined by an ELISA-based RV
antigen reduction neutralization assay (NELISA) as described
by others [42,43] with slight modifications. Two-fold dilution
series of group wise pooled and 1:10 diluted fecal samples,
VWs and sera from immunized and control mice were mixed
with Wa (G1P1A [8]) RV strain homologous to the immunizing
rVP6 protein or RRV (G3P5B [3]) containing 125 focus-forming
units (ffu). RV antibody positive human serum diluted from 1:10
was used as a positive assay control. After 1 hour incubation at
+37°C the mixtures were overlaid to confluent MA104 cell
monolayers in 96-well cell culture plates (Nunc, Roskilde,
Denmark) following centrifugation for 60 min at 1000 × g. The
virus inoculum was replaced with a culture medium containing
trypsin (Sigma-Aldrich) at 4 µg/ml and the plates were
incubated for 15 h at +37°C. After lysing the cells with a thaw
freeze cycle the RV detection in duplicate samples was
performed by a Ridascreen® kit (R-Biopharm AG, Darmstadt,
Germany) according to the manufacturer’s instructions. A
reduction in OD value greater than 60% compared with the
positive control wells (trypsin activated RV without the test
sample) was considered to indicate neutralization. Neutralizing
titers were expressed as the highest sample dilution yielding
neutralization.
Detection of interferon-γ (IFN-γ) producing T cells
NoV and RV-specific T cell responses were analyzed by
quantification of IFN-γ production from splenocytes by
ELISPOT [38] with slight modifications. Ninety-six well
MultiScreenHTS-IP filter plates (Millipore, Billerica, MA) were
coated with monoclonal anti-mouse IFN-γ (Mabtech Ab, Nacka
Strand, Sweden) at 5 µg/ml. After blocking the plates with 10%
fetal bovine serum (FBS, Sigma-Aldrich) the antigens and the
cells in the culture media (CM, RPMI-1640 supplemented with
100 U/ml penicillin, 100 µg/ml streptomycin, 50 µM 2-
mercaptoethanol and 2 mM L-glutamine, all purchased from
Sigma-Aldrich) and 5% FBS were added. NoV capsid-derived
synthetic 15-mer peptides (Proimmune Ltd., Oxford, UK)
identical to a published T-cell epitope of GII-4
(CLLPQEWVQHFYQEA, amino acids 461–475) [44] and
corresponding peptides of GII-4 NO (CLLPQEWVQYFYQEA)
and GII-12 (CLLPQEWIQHLYQES) were used at 5 µg/ml to
stimulate individual mouse splenocytes (0.1x106 cells/well) for
NoV-specific INF-γ production. For detection of RV-specific
IFN-γ producing cells, group-wise pooled splenocytes were
stimulated with VP6 derived 18-mer peptide previously
Trivalent Combination Vaccine against NoV and RV
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identified as a VP6-specific CD4+ T cell epitope
(DGATTWYFNPVILRPNNV, amino acids 242-259) [45] at 5
µg/ml or RV cell culture antigens (Wa G1P1A [8], BrB G4P2
[6], WC3 G6P7 [5] and RRV G3P5B [3]) at a VP6 concentration
of 0.5 µg/ml. Mock infected MA104 cell cultures were used as a
negative control. Background control (cells with CM only) and
cell viability control (cells stimulated with 10 µg/ml of
Conacavalin A, Sigma-Aldrich) were added to each assay. The
plates were incubated for 20 h at +37°C and 5% CO2 after
which the cells were discarded and the plates were thoroughly
washed with PBS. Biotinylated anti-mouse IFN-γ monoclonal
antibody (Mabtech, 0.5 µg/ml in PBS / 0.5% FBS) was added
and the plates incubated for 2 h at RT. After washing, 1:1000
diluted streptavidin-ALP (Mabtech) was added and the plates
were incubated for 1h. The spots were developed with
BCIP/NBT substrate (Mabtech) and the formation of color
reaction stopped with tap water. The spots were counted by an
ImmunoSpot® automatic CTL analyzer (CTL-Europe GmbH,
Bonn, Germany) and the results are expressed as mean spot-
forming cells (SFC) per 106 splenocytes of duplicate wells.
Statistical analyzes
A Mann–Whitney U-test was used to assess the statistical
difference between non-parametric observations of two
independent groups. Statistical analyses were done by IBM
SPSS Statistics -software (SPSS Inc., Chicago, IL) version
19.0 and the statistical significant difference was defined as p ≤
0.05.
Results
Morphology of NoV VLPs and RV rVP6 and formulation
of the trivalent vaccine
The assembly conformations of NoV GII-4 VLPs, GI-3 VLPs
and RV rVP6 were verified by transmission electron
microscopy (TEM) as described previously [36]. As illustrated
in Figure 1, recombinant BV-produced NoV VP1capsid proteins
self-assembled into the GII-4 VLPs of ~38 nm (Figure 1A) and
GI-3 VLPs (Figure 1B) of ~30 nm in diameter. RV rVP6
production resulted in conformation of VP6 trimers, which
under neutral pH conditions (PBS, pH 7.4) assembled into
tubular structures but also to a minor number of sheets (Figure
1C) [34]. The combination of both NoV VLPs and rVP6 in the
ratio of 1:1:1 resulted in the trivalent formulation where the VP6
tubules were partly filled with the VLPs (Figure 1D).
Dose response of single antigen immunizations
The optimal amount of antigens to be used in the trivalent
vaccine was pre-determined by a dose response study in
BALB/c mice immunized with 3, 10 and 30 µg of NoV GII-4
VLPs, GI-3 VLPs or RV rVP6 as single antigens. The dose
responses to each antigen were screened by measuring
antigen-specific serum IgG antibody titers in ELISA. All three
antigens induced robust systemic IgG responses in mice
(Figure 2A–C). No significant difference (p>0.05) in the levels
of IgG in the termination sera was detected between the
groups immunized with 10 and 30 µg of the antigens, whereas
a 3 µg dose raised the significantly lower IgG response to each
of the antigens (p<0.05). Additional immunological assays
including antigen-specific IgG avidity, IgG subtype ratio (IgG1/
IgG2a), IgG cross reactivity, NoV VLPs blocking activity and
intestinal antibody content confirmed the same result (data not
shown). Therefore, the 10 µg dose for each antigen was used
in the further immunogenicity studies described below.
Magnitude and avidity of antigen-specific IgG
responses and IgG subtype balance
Groups of BALB/c mice were immunized two times with 10
µg of NoV GII-4 VLPs, GI-3 VLPs or RV rVP6 as single
antigens or with the combination of all three proteins
(10+10+10 µg) and the immune responses induced in each
group were compared at study week 5. The duration of the
immune response induced by the trivalent formulation was
followed in another group of mice terminated at study week 24.
All antigens induced a robust homologous IgG response
(Figure 3A–C) and there were no statistical differences
between the immune responses induced by single antigens
versus the trivalent formulation (all p>0.05). Although
approximately one-fold decrease in the NoV-specific titers
occurred from week 5 to 24 (Figure 3A-B), the magnitude of the
response still remained high with GII-4 and GI-3-specific titers
of 4log10. Kinetics of GII-4, GI-3 and rVP6-specific IgG
measured from tail blood samples showed that after the
second immunization (at week 3) there were no variations in
the levels of antigen-specific IgGs up to study week 20 (Figure
3D). The antigen-specific IgGs were of high avidity (mean
avidity index >50%) and no statistically significant differences
(p>0.05) were observed between the single versus trivalent
combination immunizations (Figure 3E–G) at study week 5.
The avidity was long-lasting as high avidity IgGs against all
three antigens were still observed 24 weeks after the last
immunization in the majority of mice sera receiving trivalent
formulation (Figure 3E–G). Antigen-specific IgG subtype titers
for IgG1 (representing a Th2 response) and IgG2a
(representing a Th1 response) were also measured (data not
shown) and Th2/Th1 ratios determined. Trivalent immunization
resulted in GII-4, GI-3, and rVP6-specific Th2/Th1 ratios of 0.5,
0.6 and 0.8 respectively, indicating that the combination
vaccine triggers a well-balanced Th2/Th1 response.
Cross reactive antibody responses
The cross-reactivity of the serum antibodies induced by the
single versus trivalent immunizations were measured in ELISA
against heterologous NoV VLPs derived from genogroup II
(GII-4 NO and GII-12) and genogroup I (GI-1) not included in
the immunization. GII-4 and GI-3 VLP immunizations induced
high levels (mean OD>1.5) of cross-reactive antibodies against
VLPs belonging to the same genogroup and significantly lower
levels (mean OD<0.6, p<0.01) of antibodies against the VLPs
belonging to the other genogroup (Figure 4A). The trivalent
vaccine immunization triggered high levels of cross-reactive
IgGs to all NoV VLPs tested, therefore indicative of a strong
humoral response generation against both genogroups of
NoVs. In addition, similar levels of intra genogroup antibodies
(all p>0.05) were observed in the trivalent combination
Trivalent Combination Vaccine against NoV and RV
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immunized group compared with the group of VLPs immunized
separately, indicating that there was no mutual inhibition of the
antigens in the combination (Figure 4A). These cross-reactive
NoV-specific IgGs were also of long duration (Figure 4A). In
Figure 1.  Electron microscopy images of the single antigens and the trivalent combination used to immunize BALB/c
mice.  Morphological assemblies of NoV GII-4 capsid (A), GI-3 capsid (B) and RV rVP6 (C) proteins, and the trivalent combination
(1:1:1 of each antigen) of the structures depicted in panels A-C (D) were examined by transmission electron microscopy (TEM)
using a FEI Tecnai F12 electron microscope (Philips Electron Optics, Holland) with 18,500 × magnification following negative
staining with 3% uranyl acetate (UA), pH 4.6. The arrows represent each structure (A–C) in the trivalent assembly (D). Bar 100 nm.
doi: 10.1371/journal.pone.0070409.g001
Figure 2.  Antigen-specific serum IgG dose response.  Mice were immunized twice at study weeks 0 and 3 with 3, 10 and 30 µg
of single antigens and the geometric mean titers (GMTs) induced by GII-4 VLPs (A), GI-3 VLPs (B) and RV rVP6 (C) were
measured in an ELISA. The error bars represent the standard error of the means. Statistical differences between any two
experimental groups were determined by a Mann–Whitney U-test and the p-value ≤ 0.05 was considered a statistically significant
difference.
doi: 10.1371/journal.pone.0070409.g002
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Figure 3.  Serum IgG responses induced by the single antigens versus trivalent combination.  Mice were immunized two
times with 10 µg of the single antigen (GII-4 VLPs, GI-3 VLPs or rVP6) or the trivalent combination (each antigen at a 10 µg dose),
and the sera at study week 5 and 24 were tested against GII-4 VLPs (A), GI-3 VLPs (B) and rVP6 (C) in ELISA. Shown are the
geometric mean titers (GMTs) of the sera with standard errors of the means. The horizontal lines on panels A-C indicate the limit of
detection for the assay. Kinetics of GII-4, GI-3 and VP6-specific IgG responses induced by the trivalent vaccine were measured
from tail blood samples of immunized and control mice, and the OD values representing the quantity of antigen-specific IgG at any
given time point are shown (D). The avidity of GII-4 (E), GI-3 (F) and rVP6-specific (G) serum IgG antibodies was tested from
individual mouse termination sera (at 1:200 dilution) in a modified ELISA in which urea was used to strip off the low avidity
antibodies. Shown are the individual mice antigen-specific avidity indexes (%) and the boxed values at the bottom of each figure
indicate the group mean avidity indexes. The avidity index was calculated as (OD with urea/OD without urea) × 100%. Avidity index
≥ 50% was considered high avidity. Statistical differences between any two experimental groups were determined by a Mann–
Whitney U-test and the p-value ≤ 0.05 was considered a statistically significant difference.
doi: 10.1371/journal.pone.0070409.g003
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addition to the serum IgG levels represented by the OD value,
the GMTs were determined for each study group to confirm the
results of the magnitude of cross-reactive IgG response.
Similarly to the OD values, the GMTs of cross-reactive
antibodies were higher (16 to 32-fold higher, p<0.05) in the
trivalent than single immunized mice groups when considering
inter genogroup responses (data not shown).
Cross-reactive antibodies against seven RV cell culture
antigens belonging to human (G1PA [8], G4P2 [6], G2P2 [6],
G8P4 [10] and G12P [4]), bovine (G6P7 [5]), and rhesus RV
strains (G3P5B [3]) were detected in mice sera after rVP6
immunization (Figure 4B). No difference in the antibody levels
(p>0.05) were noted whether rVP6 was administered alone or
in the trivalent combination with NoV VLPs. The magnitude of
the response was somewhat lower at the week 24 than at week
5 but still high levels of cross-reactive antibodies (mean OD
1.3-2.0) were detected (Figure 4B).
Mucosal antibodies and serum VP6 specific IgA
Intestinal NoV and RV-specific IgG were measured from
group-wise pooled 10% fecal suspensions in ELISA. Moderate
levels of antigen-specific intestinal anti-GII-4 IgG (Figure 5A),
anti-GI-3 IgG (Figure 5B), and anti-VP6 IgG (Figure 5C) were
detected after each antigen immunizations alone or in the
trivalent combination. The stool suspensions from the negative
control mice were all IgG negative (Figure 5A–5C). VW
samples at study week 5 from the mice immunized with the
trivalent combination were tested in ELISA for the detection of
RV-specific IgG and IgA antibodies. A moderate level of rVP6-
specific IgG and a low level of rVP6-specific IgA were detected
from VW samples (Figure 5D). A low level of VP6 specific IgA
(OD 0.176, at a 1:2 dilution) was detected from the trivalent
combination immunized mice serum (data not shown).
NoV blocking assays and RV inhibition assay
Saliva blocking assays were conducted to study blocking of
homologous (immunogen-specific) and heterologous (non-
immunogen-specific) NoV VLPs binding to the saliva HBGAs
with mice antiserum (Figure 6). Group-wise pooled sera of
mice immunized with the single antigen or the trivalent
combination blocked homologous GII-4 (Figure 6A) and GI-3
(Figure 6B) VLP binding to saliva HBGAs with a similar
intensity. The serum titers for total (100%) blocking of the
homologous VLPs binding to the saliva were at maximum
1:400 for GII-4 and 1:200 for GI-3 VLPs. However, mice sera
immunized with the GI-3 VLPs alone did not cross-block
binding of GII-4 to the saliva (Figure 6A). Likewise, sera of
mice immunized with the GII-4 VLPs alone did not cross-block
GI-3 VLP binding (Figure 6B). These results indicate that NoV
cross-genogroup blocking activity cannot be induced with a
single NoV VLP immunization, although cross-reactive binding
antibodies were detected in ELISA (Figure 4A). The trivalent
combination immunized mice sera were able to block both of
the VLPs binding with a similar intensity as the single VLPs
immunized mice, and these activities were preserved for the
whole 24-week study period (Figure 6A and 6B). Serum
blocking of non-immunogen GII-4 NO VLPs (Figure 6C) and
GI-1 VLPs (Figure 6D) binding to the saliva was also obtained
genogroup-wise; GII-4 immunization induced GII-4 NO and
GI-3 immunization GI-1 blocking antibodies. The heterologous
blocking activity against VLPs inside the genogroup was similar
whether the antigen was administered alone or in the trivalent
combination vaccine (Figure 6C and 6D) and lasted until study
week 24.
To detect the functionality of VP6-specific antibodies fecal
suspensions, VWs and sera were used to inhibit RV infectivity
in vitro by ELISA-based antigen-reduction neutralization assay
[42,43]. Our attempts to use fecal suspensions in the assay
failed, probably because of the toxicity of the suspensions for
MA104 cells, as previously shown by others [46]. Therefore, we
used VWs instead, which likewise to fecal suspensions, contain
mucosal antibodies as described above. Inhibition of the
infectivity of RVs Wa (G1P1A [8]), homologous to the
immunizing protein and RRV (G3P5B [3]), was detected with
the VW of the trivalent combination immunized mice with
maximum neutralizing titers of 1:160 and 1:320, respectively
(Figure 6E). The VW samples from negative control mice did
not inhibit RV infection, whereas the positive human control
serum neutralized both viruses (Figure 6E). In addition, mouse
immune sera did not inhibit RV infectivity in vitro (data not
shown). The experiments were repeated several times with
consistent results.
Cell mediated immune responses
NoV and RV-specific IFN-γ producing cells were quantified
from mice splenocytes by an ELISPOT assay (Figure 7). Mice
immunized with the GII-4 VLPs or the trivalent combination
vaccine elicited a robust IFN-γ response when stimulated with
the 15-mer peptides representing capsid P-domain T-cell
epitopes [44] derived from homotypic GII-4 or heterotypic GII-4
NO and GII-12 genotypes as described in Materials and
Methods. No statistically significant difference was observed in
any responses between these experimental groups (p>0.05) at
study week 5 (Figure 7A). The IFN-γ response induced by the
trivalent vaccine did not diminish over time as IFN-γ producing
cell frequency was similar (p>0.05) at study week 5 and 24.
GI-3 VLP immunization did not induce any cross-reactive IFN-γ
responses to any of the GII peptides. No IFN-γ responses were
detected to any peptides by the cells of negative control mice.
Immunization with rVP6 either as a single antigen or in the
trivalent combination resulted in considerable IFN-γ production
when the cells were stimulated with the synthetic peptide
representing CD4+ T cell epitope [45] or RV cell culture
antigens Wa G1P1A [8], BrB G4P2 [6], bov WC3 G6P7 [5] and
rhesus RV G3P5B [3] (Figure 7B). IFN-γ responses were
detected against all stimulants at study week 24 but the
magnitude of IFN-γ response was up to 3-fold lower in some
instances compared with study week 5. No response to mock-
infected MA104 cells was detected in any immunized group
(Figure 7B) while cell viability was similar in all groups
controlled by Con A stimulation (data not shown).
Discussion
In our previous work we introduced the concept of
vaccinating against NoV and RV by parenteral injection of a
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PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e70409
Figure 4.  Cross-reactive serum IgG antibodies.  Mice were immunized two times with 10 µg of the single antigen (GII-4 VLPs,
GI-3 VLPs or rVP6) or the trivalent combination (each antigen at a 10 µg dose) and the sera were tested against heterologous NoV
VLPs (A) and RV cell culture antigens (B) in ELISA. Shown are experimental and control groups’ mean OD values representing the
quantity of antigen-specific IgG. The error bars represent standard errors of the mean. A Mann–Whitney U-test was used to
determine statistical differences between single antigen-induced IgG quantities compared with trivalent vaccine induced IgG
quantities at study week 5 and IgG quantities induced by the trivalent vaccine at study weeks 5 and 24. The p-value ≤ 0.05 is
considered a statistically significant difference.
doi: 10.1371/journal.pone.0070409.g004
Trivalent Combination Vaccine against NoV and RV
PLOS ONE | www.plosone.org 8 July 2013 | Volume 8 | Issue 7 | e70409
dual combination vaccine consisting of NoV GII-4 VLPs and RV
rVP6 [7]. In the present study we have included GI-3 VLPs as a
representative of GI NoVs in the dual vaccine candidate and
generated a trivalent combination in an attempt to develop
potentially neutralizing cross-reactive antibody responses
against GI and GII of NoVs. We also investigated induction of
NoV and RV-specific cell mediated immunity as well as RV
inhibition by VP6-specific antibodies.
Genogroup I NoVs are antigenically very well conserved [47]
and we have chosen GI-3 genotype in the trivalent vaccine
combination as it is an important agent in NoV outbreaks and
has been the most prevalent GI genotype in pediatric NoV
gastroenteritis in Finland in recent years [3]. We hypothesized
that by combining VLPs derived from GII-4, the most prevalent
NoV genotype worldwide [14], and GI-3 in a single vaccine
would give the substantial amount of cross-reactivity needed
from a broadly effective NoV vaccine. Recombinant VP6
protein was selected as a part of the trivalent combination
vaccine as numerous studies in animal models have
documented the protective role of VP6-specific antibodies and
T cells in RV infection [30–33]. Both NoV VLPs and rVP6
tubular structures are optimal for dentritic cells uptake [48,49].
The size difference observed between GII-4 and GI-3 VLPs
(~38 nm and ~30 nm, respectively) did not affect the
immunogenicity of the VLPs as similar immune responses were
induced with both of these particles. Although we did not
attempt to identify the reason/s for the VLPs size difference, it
may be that different number of VP1 monomers are assembled
in a single VLP similarly to observations made by White et al.
[50]. In addition, natural amino acid differences in the VP1
proteins may drive different size VLP formation [51].
The results from the present study show that two IM
immunizations with NoV GII-4 or GI-3 VLPs, either alone or in
the trivalent combination with RV rVP6 without an external
adjuvant, induced a strong, long-lasting antigen-specific IgG
response in mice. In addition the presence of NoV IgG in the
Figure 5.  Mucosal antibody response.  Group-wise pooled stool samples (10% suspension) of mice immunized with the single
NoV GII-4 VLPs, GI-3 VLPs or RV rVP6 antigens or the trivalent combination vaccine were titrated two-fold and anti-GII-4 (A), anti-
GI-3 (B) and anti-VP6 (C) IgG content was measured in ELISA. Anti-VP6 IgG and IgA antibodies were measured from the trivalent
combination vaccine immunized and control mice vaginal wash samples diluted 1:5 for IgG detection and 1:2 for IgA detection (D).
Shown are experimental and control groups’ mean OD values representing the quantity of antigen-specific antibody.
doi: 10.1371/journal.pone.0070409.g005
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Figure 6.  Functionality of NoV and RV-specific antibodies.  Termination sera of mice immunized with the single NoV GII-4 or
GI-3 VLPs antigens or the trivalent combination vaccine were pooled group-wise, titrated two-fold and used for blocking the binding
of homologous GII-4 and GI-3 VLPs (A, B) or heterologous GII-4 NO and GI-1 VLPs (C, D) to human secretor positive saliva (type A
for GII-4, GII-4 NO and GI-3 binding and type O for GI-1 binding). Serum from mice receiving the carrier only (PBS) was used as a
negative control. The blocking index (%) was calculated as 100% – (OD wells with serum/OD wells without serum, maximum
binding) × 100%. Vaginal washes of mice immunized with the trivalent combination vaccine were tested for inhibition of human RV
Wa (G1P1A [8]) strain homologous to the immunizing rVP6 protein, or rhesus RV (G3P5B [3]) infectivity by neutralizing ELISA
(NELISA). Vaginal washes of mice receiving the carrier only (PBS) and serum from a RV seropositive human donor were used as
negative and positive controls. Results are shown as the mean percentage (%) inhibition of rotavirus infectivity of duplicate wells
with standard errors. A dashed horizontal line indicates 60% reduction in virus infectivity.
doi: 10.1371/journal.pone.0070409.g006
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Figure 7.  NoV and RV-specific IFN-γ responses.  Splenocytes of mice immunized with the single NoV GII-4 or GI-3 VLPs or the
trivalent combination vaccine were stimulated with synthetic NoV capsid-derived 15-mer peptides from different NoV genotypes and
analyzed for IFN-γ production by an ELISPOT assay (A). The mean spot forming cells (SFC)/106 cells are shown. The error bars
represent the standard errors of the mean. The statistical differences between any two experimental groups’ response to a given
peptide were determined by a Mann–Whitney U-test and the p-value ≤ 0.05 was considered a statistically significant difference.
Splenocytes of rVP6 or the trivalent vaccine immunized mice were pooled group-wise and stimulated with synthetic VP6-derived 18-
mer peptide or RV cell culture antigens and analyzed for IFN-γ production by the ELISPOT (B). Splenocytes from mice receiving the
carrier only (PBS) were used as negative control cells. The mean spot forming cells (SFC)/106 cells of the replicate wells are shown.
The dashed line in each figure indicates the maximum background level (cut-off limit) obtained from cells incubated in a culture
media (CM) only (mean SFC/106 + 3× SD).
doi: 10.1371/journal.pone.0070409.g007
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gut lumen as detected in here is considered to be an important
mechanism in protection against gut infection [52]. As NoVs
have great antigenic diversity and are fast evolving viruses, the
antibody response elicited by NoV vaccine should be cross-
reactive across GI and GII genogroups [19,53]. Our results
show that a robust cross-reactive NoV antibody response
against both genogroups was solely achieved by the trivalent
vaccine, whereas single vaccinations induced a much stronger
intra than inter genogroup antibody response. Virus
neutralizing potential of the antibodies is an important correlate
of protection [6,40,54]. As the traditional neutralization assay is
not an option for NoVs that are not able to grow in cell cultures
[9], a surrogate neutralization assay named blocking assay
using NoV VLPs and HBGAs has been developed instead
[41,55]. We have detected high titer of type-specific blocking
antibodies in the sera of immunized mice and each antisera
was able to block binding of the heterologous VLPs not
included in the immunizing formulation but belonging to the
same NoV genogroup, namely GII-4 NO and GI-1 VLPs.
However, neither GII-4 nor GI-3 VLP immunization alone could
induce blocking antibodies towards the VLPs from the other
genogroup although cross-reactive binding antibodies were
induced (Figure 4A). These observations are in line with the
previous findings showing that blocking antibodies are
genogroup specific and there is very little inter genogroup
blocking activity [47,53,54]. When GII-4 and GI-3 VLPs were
combined in the trivalent vaccine, the mice antiserum could
block binding of the immunizing and non-immunizing VLPs
from both genogroups. The data obtained herein further
supports the hypothesis that only multivalent NoV vaccination
will induce broadly protective NoV immunity [17–19,53].
The research involving NoV immunity has been largely
focused on the antibodies however, cell-mediated immune
responses might be important in the clearance of NoV, as has
been shown for other viruses [56,57]. We have detected that T
cells in the immunized mice produce high levels of IFN-γ in
response to synthetic peptides representing T cell epitopes
derived from the immunizing (GII-4) [44] and heterotypic
(GII-12 and GII-4 NO) NoV genotypes. Lindesmith and co-
workers [58] have shown that T cell responses (specifically
IFN-γ and IL-2 production) might have been associated with
protection in NoV challenge study.
Due to the highly conserved nature [28] RV VP6 protein
could provide protection against a broad range of RV
serotypes. Although VP6 does not induce serum neutralizing
antibodies it has been suggested that VP6 confers protection in
mice by inducing a strong CD4+ T-cell response [59] and/or by
stimulating mucosal antibodies, especially IgA [60–62]. Our
results show that rVP6 assembled in tubular forms is very
immunogenic in mice, stimulating a robust, long lasting, high
avidity IgG response in serum reactive with various RV strains.
Anti-rVP6-specific IgG and IgA were also found in the mucosal
samples indicating that an anti-VP6 antibody was being
transferred to the gut, the location where the first line of
defense is taking place. These mucosal VP6-specific
antibodies in contrast to the serum antibodies, inhibited human
and rhesus RV infectivity in vitro, indicative of the heterotypic
protective antibody induction against RVs. Although the
mechanism of inhibition remains to be determined, we believe
that VP6-specific mucosal IgG and especially IgA are
responsible for the inhibition. To support of this, although high
level of VP6-specific IgG and low level of VP6-specific IgA
were present in serum as well, it did not inhibit RV infectivity.
Others have shown that RV VP6 protection from RV infection in
vitro and in vivo was mediated by the VP6-specific mucosal IgA
and not the VP6-specific serum antibodies [60–64]. Although
IM immunization usually elicits systemic immune responses
without decent mucosal immunity, it has been shown [65] that
naïve B cells acting as antigen presenting cells (APC) are
responsible for RV-specific IgA production in the gut after
parental immunization in mice. After IM inoculation these APC
migrate from draining lymph nodes to mucosal lymphoid tissue,
where they induce the production of virus-specific IgA secreting
cells. Indeed, Parez and co-workers [66] have shown that
specifically RV VP6 protein interacts with a large fraction of
naïve B cells via surface immunoglubulins.
We also observed that the cellular immune responses were
activated upon rVP6 immunization as the cells of immunized
mice produced IFN-γ when stimulated with the VP6-derived
peptide representing CD4+ T cell epitope [45] or with various
RV cell culture antigens. In our earlier work we have identified
CD4+ T cells as being the principal lymphocyte population
accountable for IFN-γ production [67]. McNeal and co-workers
have shown that CD4+ T cells as the ones we describe here,
are the only lymphocyte population responsible for the
protective immunity against murine RV [31].
Our results show that the trivalent vaccine consisting of NoV
GII-4 and GI-3 VLPs and RV rVP6 1) stimulates strong
systemic cross-reactive antibody responses to both viruses
with inter NoV genogroup neutralizing ability; 2) induces
mucosal antibodies able to inhibit RVs infectivity; and 3)
activates the cellular arm of the immune responses to both
viruses. Importantly, all the immune responses induced by the
trivalent vaccine were long-lasting and no mutual interference
and/or inhibition of the vaccine components in the formulation
was observed. The results obtained here are encouraging and
support the development of a non-live subunit combination
vaccine against NoV and RV for humans.
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